Physician profile
Debra Karnasiewicz
NPI 1962445254
$4,474.46
in general payments reported to CMS, 2019-2025
47 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $365 · 2021: $612 · 2022: $583 · 2023: $522 · 2024: $427 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Consulting Fee: $14.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.92 |
| Consulting Fee | $14.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $617.56 | 2019-2025 | Wegovy |
| Amgen INC. | $591.19 | 2019-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $428.49 | 2019-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $347.80 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Abbvie INC. | $277.54 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $265.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $243.12 | 2019-2024 | |
| Pfizer INC. | $198.32 | 2019-2023 | |
| Viiv Healthcare Company | $162.42 | 2022-2025 | Rukobia, Apretude |
| Horizon Therapeutics Plc | $111.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.51 | 2019-2022 | |
| Janssen Biotech, INC. | $76.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.79 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $59.14 | 2019-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $57.05 | 2023-2024 | Rexulti, Abilify Mycite |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Karnasiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.